41 results
8-K
EX-99.1
MAIA
MAIA Biotechnology, Inc.
27 Feb 24
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
5:23pm
in guiding oncology assets through all stages of development, from research to clinical strategies and registration. His extensive engagement
8-K
EX-1.1
MAIA
MAIA Biotechnology, Inc.
14 Feb 24
Entry into a Material Definitive Agreement
5:15pm
of the Company and (c) the Company’s engagement of the Manager in connection with the offering and the process leading up to the offering is as independent
8-K
EX-4.2
MAIA
MAIA Biotechnology, Inc.
17 Nov 23
MAIA Biotechnology Announces $4 Million Registered Direct Offering
9:09am
to that certain Engagement Agreement between the Company and H.C. Wainwright & Co., LLC, dated as of November 4, 2023.
Section 1. Definitions. Capitalized
8-K
lu4lx4o
17 Nov 23
MAIA Biotechnology Announces $4 Million Registered Direct Offering
9:09am
424B5
5m3ov7k6nuevp3qyilm
17 Nov 23
Prospectus supplement for primary offering
9:06am
DRS
pb5wtxc1d85yylm2g2
1 Jun 23
Draft registration statement
12:00am
8-K
EX-1.1
pftwlxr
27 Apr 23
MAIA Biotechnology, Inc. Announces Pricing of Public Offering
5:25pm
424B4
g7nb5m2bo2nv
25 Apr 23
Prospectus supplement with pricing info
7:45pm
DEF 14A
b6c wmpfz
19 Apr 23
Definitive proxy
4:06pm
DRS
f86 z6y0779
23 Dec 22
Draft registration statement
12:00am
8-K
4po011
21 Nov 22
Changes in Registrant's Certifying Accountant
9:38pm
S-8
EX-99.3
y38 g48dq
1 Aug 22
Registration of securities for employees
5:30pm